Atrion Reports Fourth Quarter and Full Year 2006 Results Diluted EPS Were up 38% for the Quarter and 18% for the Year ALLEN, Texas--(BUSINESS WIRE)

ATRION CORPORATION EXHIBIT 99.1

Atrion Reports Fourth Quarter and Full Year 2006 Results

Diluted EPS Were up 38% for the Quarter and 18% for the Year

ALLEN, Texas--(BUSINESS WIRE)--Feb. 15, 2007--Atrion Corporation

(Nasdaq:ATRI) announced today higher revenues and earnings per share

for the fourth quarter and the full year 2006. Revenues for the fourth

quarter of 2006 were $21,379,000 compared to $17,003,000 in the same

period of 2005, representing a 26% increase. On a diluted per share

basis, net income for the quarter increased 38% to $1.52 from $1.10 in

the fourth quarter of 2005. Atrion's revenues for the full year of

2006 increased 12% to $81,020,000 from $72,089,000 in 2005. Net income

per diluted share of $5.51 in 2006 was 18% higher than 2005's net

income of $4.66 per diluted share.

Commenting on the Company's performance for the fourth quarter

compared to fourth quarter of 2005, Emile A. Battat, Chairman & CEO

said, "We are very pleased with the record growth in revenues

resulting from an unexpected spike in customer demand across many of

our products lines and the return of our ophthalmic shipments to

anticipated levels. By design, each of our manufacturing facilities is

now able to respond to surges in demand as and when they occur, an

advantage over most of our competitors. Of the $4.4 million increase

in revenues during the quarter, 35% was attributed to Fluid Delivery,

27% to Ophthalmology, 21% to Cardiovascular and 17% to Other.

Operating income increased 31%, while net income and diluted EPS

increased 38% each."

Mr. Battat further stated, "During 2006, we completed the

construction of a new manufacturing facility in Florida and

successfully met the challenge of transitioning our production to the

new plant. This was accomplished while growing revenues for the year

by 12% and diluted EPS by 18% compared to 2005. 2006 marked the eighth

consecutive year in which per share earnings from operations rose at

double digit rates. We are extremely pleased with these results."

Mr. Battat added, "The agreement for the sale of our natural gas

pipeline in 1997 called for certain contingent annual payments through

2006. In the intervening years we received $250,000 annually. We will

not enjoy this income from discontinued operations in 2007 and

subsequent years. Also in 2007 we expect our income tax rate to

increase to 31% compared to 25% in 2006. As a result, we believe that

for the year 2007, operating income rather than net income would be

the appropriate measure of comparative performance relative to 2006.

We are hopeful that this measure will show growth in excess of 15% for

Atrion Corporation designs, develops, manufactures, sells and

distributes products and components primarily to medical markets

The statements in this press release that are forward-looking are

based upon current expectations and actual results or future events

may differ materially. Such statements include, but are not limited

to, Atrion's expectations regarding the Company's income tax rate in

2007 and growth in operating income in 2007. Words such as "expects,"

"believes," "anticipates," "intends," "will," and "should" and

variations of such words and similar expressions are intended to

identify such forward-looking statements. These statements involve

risks and uncertainties. The following are some of the factors that

could cause actual results or future events to differ materially from

those expressed in or underlying our forward-looking statements:

changing economic, market and business conditions; acts of war or

terrorism; the effects of governmental regulation; competition and new

technologies; slower-than-anticipated introduction of new products or

implementation of marketing strategies; the Company's ability to

protect its intellectual property; changes in the prices of raw

materials; changes in product mix; and intellectual property and

product liability claims and product recalls. The foregoing list of

factors is not exclusive, and other factors are set forth in the

Company's filings with the SEC.

CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except per share data)

Three Months Twelve Months

December 31, December 31,

----------------- -----------------

-------- -------- -------- --------

Revenues $21,379 $17,003 $81,020 $72,089

Cost of goods sold 12,539 9,822 48,572 43,119

-------- -------- -------- --------

Gross profit 8,840 7,181 32,448 28,970

Operating expenses 4,866 4,144 18,110 16,272

-------- -------- -------- --------

Operating income 3,974 3,037 14,338 12,698

Interest income (expense), net (130) 5 (162) (24)

Other income, net 22 -- (4) 10

-------- -------- -------- --------

Income from continuing operations

before provision for income taxes 3,866 3,042 14,172 12,684

Income tax provision (887) (893) (3,572) (3,891)

-------- -------- -------- --------

Income from continuing operations 2,979 2,149 10,600 8,793

Gain on disposal of discontinued

operations -- -- 165 165

-------- -------- -------- --------

Net income $ 2,979 $ 2,149 $10,765 $ 8,958

======== ======== ======== ========

Income per basic share:

Income from continuing

operations $ 1.60 $ 1.17 $ 5.73 $ 4.90

Gain on disposal of discontinued

operations -- -- .09 .09

-------- -------- -------- --------

Net income per basic share $ 1.60 $ 1.17 $ 5.82 $ 4.99

======== ======== ======== ========

Weighted average basic shares

outstanding 1,865 1,833 1,851 1,794

======== ======== ======== ========